ATE276366T1 - Type f botulinum toxin und seine verwendung - Google Patents

Type f botulinum toxin und seine verwendung

Info

Publication number
ATE276366T1
ATE276366T1 AT96917600T AT96917600T ATE276366T1 AT E276366 T1 ATE276366 T1 AT E276366T1 AT 96917600 T AT96917600 T AT 96917600T AT 96917600 T AT96917600 T AT 96917600T AT E276366 T1 ATE276366 T1 AT E276366T1
Authority
AT
Austria
Prior art keywords
toxin
type
botulinum toxin
fragment
fusion protein
Prior art date
Application number
AT96917600T
Other languages
English (en)
Inventor
Michael James Elmore
Margaret Lamble Mauchline
Nigel Peter Minton
Vladimir Artymovich Pasechnik
Richard William Titball
Original Assignee
Health Prot Agency
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Health Prot Agency filed Critical Health Prot Agency
Application granted granted Critical
Publication of ATE276366T1 publication Critical patent/ATE276366T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT96917600T 1995-06-12 1996-06-12 Type f botulinum toxin und seine verwendung ATE276366T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9511909.5A GB9511909D0 (en) 1995-06-12 1995-06-12 Vaccine
PCT/GB1996/001409 WO1996041881A1 (en) 1995-06-12 1996-06-12 Type f botulinum toxin and use thereof

Publications (1)

Publication Number Publication Date
ATE276366T1 true ATE276366T1 (de) 2004-10-15

Family

ID=10775930

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96917600T ATE276366T1 (de) 1995-06-12 1996-06-12 Type f botulinum toxin und seine verwendung

Country Status (12)

Country Link
US (1) US7041792B2 (de)
EP (1) EP0833919B1 (de)
JP (1) JP4005633B2 (de)
AT (1) ATE276366T1 (de)
AU (1) AU705944B2 (de)
CA (1) CA2224444C (de)
DE (1) DE69633389T2 (de)
DK (1) DK0833919T3 (de)
ES (1) ES2224171T3 (de)
GB (1) GB9511909D0 (de)
PT (1) PT833919E (de)
WO (1) WO1996041881A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7214787B1 (en) * 1993-09-21 2007-05-08 United States Of America As Represented By The Secretary Of The Army Recombinant vaccine against botulinum neurotoxin
DE19735105A1 (de) * 1997-08-13 1999-03-04 Univ Albert Ludwigs Freiburg Transportsystem zur Einbringung von Proteinen in Zielzellen mit Hilfe eines Fusionsproteins, Nucleinsäurekonstrukte kodierend für die Komponenten des Transportsystems und Arzneimittel, die Komponenten des Transportsystems umfassen
AU4641299A (en) * 1998-07-22 2000-02-14 Agricultural Research Council Vaccine comprising a non-toxic immunogenic derivative of (clostridium botulinum)type d neurotoxin
EP1180999A4 (de) * 1999-05-12 2005-03-30 Us Army Medical Res And Materi Rekombinanter impfstoff gegen botulinum-neurotoxin
US20060073208A1 (en) * 2004-10-01 2006-04-06 Allergan, Inc. Cosmetic neurotoxin compositions and methods
GB0525213D0 (en) * 2005-12-12 2006-01-18 Secr Defence Vaccine
ES2634669T3 (es) 2011-02-08 2017-09-28 Halozyme, Inc. Composición y formulación lipídica de una enzima de degradación de hialuronano y uso de la misma para el tratamiento de la hiperplasia benigna de próstata
KR102175159B1 (ko) * 2018-12-28 2020-11-05 대한민국 재조합 벡터, 형질전환 대장균, 보툴리눔 d/c형 중쇄 c말단 유래의 재조합 단백질을 포함하는 백신 조성물 및 키트
JPWO2024135197A1 (de) 2022-12-22 2024-06-27

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4015911A1 (de) * 1989-09-19 1991-03-28 Max Planck Gesellschaft Impfstoff gegen die lyme-krankheit
US5736139A (en) * 1989-10-31 1998-04-07 Ochidian Pharmaceuticals, Inc. Treatment of Clostridium difficile induced disease
JP3633933B2 (ja) 1992-07-31 2005-03-30 アカンビス、リサーチ、リミテッド 弱毒化細菌における組換え融合タンパク質の発現
GB9305919D0 (en) * 1993-03-22 1993-05-12 Health Lab Service Board Botulinum toxin polypeptides and their use as vaccines

Also Published As

Publication number Publication date
ES2224171T3 (es) 2005-03-01
DK0833919T3 (da) 2005-01-17
GB9511909D0 (en) 1995-08-09
AU705944B2 (en) 1999-06-03
US20020081304A1 (en) 2002-06-27
DE69633389T2 (de) 2005-10-27
AU6012196A (en) 1997-01-09
PT833919E (pt) 2005-01-31
EP0833919A1 (de) 1998-04-08
CA2224444A1 (en) 1996-12-27
JPH11507827A (ja) 1999-07-13
US7041792B2 (en) 2006-05-09
DE69633389D1 (de) 2004-10-21
WO1996041881A1 (en) 1996-12-27
CA2224444C (en) 2010-02-16
JP4005633B2 (ja) 2007-11-07
EP0833919B1 (de) 2004-09-15

Similar Documents

Publication Publication Date Title
FI974432A0 (fi) Grampositiivisten bakteerien käyttö rekombinanttiproteiinien ilmentämiseksi
EP0797659A4 (de) Insektizides proteintoxin von photorhabdus
BR9504791B1 (pt) composto de polipeptìdeo e composição farmacêutica.
IS4345A (is) Setin N-(indól-2-karbónýl)-b-alaninamíð, notkun þeirra og lyfjaefnablöndur
DZ2086A1 (fr) Benzylaminopipéridines substituées et compositionspharmaceutiques les contenant.
DE69434511D1 (de) Botulinumtoxin zur Behandlung von Dystonie
DK0643608T3 (da) Proteinrensning
DE69435307D1 (de) Bazillus Thuringiensis und dessen insektizide Proteine
DE69839566D1 (de) Chimäre polypeptide, die das fragment b des shigatoxins sowie peptide von therapeutischem interesse enthalten
FI20000353L (fi) 3,4,4-trisubstituoidun piperidinyyli-N-alkyylikarboksylaatin valmistus ja välituotteet
FI944802L (fi) HLE-proteiinien aktiivisuutta inhiboivat laktaamidipeptidit
DE69633389D1 (de) Type f botulinum toxin und seine verwendung
FI972384L (fi) Uudet dipeptidiset p-amidinobentsyyliamidit, jotka sisältävät N-terminaalisia sulfonyyli- tai amidinosulfonyyliryhmiä
EP0626450A3 (de) Ubiquitinkonjugierendes Enzym (E2) enthaltende Fusionsproteine.
DE68917837D1 (de) Peptid-Verbindungen.
NO980296D0 (no) Forbedrede terapeutiske midler
DE19681439T1 (de) Modifizierung von Polypeptidarzneimitteln zur Erhöhung des Elektrotransportflusses
FI956178A0 (fi) Varsibromelaiiniproteaasin lääkekäyttö
FR2732978B1 (fr) Vecteur viral recombinant, composition pharmaceutique le contenant et cellules transformees correspondantes
NO944025L (no) Forbedret fremstilling av rekombinant protein
EP0723454A4 (de) Für die immun- und cns-therapir nutzbare, neuartige tripeptide
FI946031A7 (fi) Kringleä sisältävien proteiinien puhdistus ja etenkin t-PA:n
DK75393D0 (da) Production of protein
FR2718028B1 (fr) Nouvelles compositions cosmétiques ou dermopharmaceutiques contenant des hydrolysats peptidiques modifiés.
ATE102214T1 (de) Homocyclostatin und cyclostatin enthaltende polypeptide als antihypertensiva.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0833919

Country of ref document: EP

EEIH Change in the person of patent owner